Molecular Biology of Oral Cavity Squamous Cell Carcinoma

Otolaryngologic Clinics of North America

Volumn 39, Issue 2, 2006, Pages 229-247

  Kupferman, Michael E ^a   Myers, Jeffrey N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; CHEMOKINE RECEPTOR ANTAGONIST; CYCLIN D1; DALTEPARIN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; JANUS KINASE; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR INHIBITOR; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53; PROTEIN TYROSINE KINASE INHIBITOR; SIBROTUZUMAB; STAT3 PROTEIN; SURAMIN; SURVIVIN; THROMBOCYTE GROWTH FACTOR ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; UVOMORULIN; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; VASCULOTROPIN INHIBITOR;

ADIPOSE TISSUE; ANGIOGENESIS; APOPTOSIS; CANCER CONTROL; CANCER GENETICS; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER THERAPY; CAPILLARY; CARCINOGENESIS; CARCINOMA IN SITU; CELL AGING; CELL DIVISION; CELL FUNCTION; CHEMICAL MUTAGENESIS; CLINICAL TRIAL; COLON CANCER; CONNECTIVE TISSUE; DIGESTIVE SYSTEM CANCER; DNA HYPERMETHYLATION; DNA METHYLATION; DNA REPLICATION; DNA REPLICATION ORIGIN; DYSPLASIA; EPITHELIUM; GENE INACTIVATION; GENE MUTATION; GENOMICS; GROWTH INHIBITION; HEAD AND NECK CARCINOMA; HETEROZYGOSITY LOSS; HUMAN; INCIDENCE; LYMPH NODE METASTASIS; MICROENVIRONMENT; MITOSIS; MOLECULAR BIOLOGY; MOLECULAR GENETICS; MOUTH CARCINOMA; MOUTH CAVITY; NUCLEOTIDE SEQUENCE; ODONTOGENIC TUMOR; ONCOGENE; PROTEOMICS; REVIEW; SALIVARY GLAND; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TOOTH FLORA; TUMOR SUPPRESSOR GENE; TUMOR VASCULARIZATION; VIRUS CARCINOGENESIS; WART VIRUS;

CARCINOMA, SQUAMOUS CELL; CELL CYCLE; CELL TRANSFORMATION, NEOPLASTIC; DNA, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR BIOLOGY; MOUTH NEOPLASMS; MUTATION; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; ONCOGENES;

EID: 33645851349     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2005.11.003     Document Type: Review

References (72)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
3. Dobrossy L. Epidemiology of head and neck cancer: magnitude of the problem. Cancer Metastasis Rev 24 (2005) 9-17
4. Cooper J.S., Pajak T.F., Forastiere A.A., et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med 350 (2004) 1937-1944
5. Kufe D.W., Holland J.F., Frei E., and American Cancer Society. Cancer medicine. 6th edition (2003), BC Decker, Lewiston p. 2
6. Mao L., Hong W.K., and Papadimitrakopoulou V.A. Focus on head and neck cancer. Cancer Cell 5 4 (2004) 311-316
7. Slaughter D.P., Southwick H.W., and Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 6 (1953) 963-968
8. Fearon E.R., Hamilton S.R., and Vogelstein B. Clonal analysis of human colorectal tumors. Science 238 (1987) 193-197
9. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
10. Califano J., van der Riet P., Westra W., et al. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res 56 (1996) 2488-2492
11. Mao L., Lee J.S., Fan Y.H., et al. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment. Nat Med 2 (1996) 682-685
12. Boyle J.O., Hakim J., Koch W., et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 53 (1993) 4477-4480
13. Waridel F., Estreicher A., Bron L., et al. Field cancerisation and polyclonal p53 mutation in the upper aero-digestive tract. Oncogene 14 (1997) 163-169
14. Blackburn E.H. Switching and signaling at the telomere. Cell 106 (2001) 661-673
15. Mao L., El-Naggar A.K., Fan Y.H., et al. Telomerase activity in head and neck squamous cell carcinoma and adjacent tissues. Cancer Res 56 (1996) 5600-5604
16. Kresty L.A., Mallery S.R., Knobloch T.J., et al. Alterations of p16(INK4a) and p14(ARF) in patients with severe oral epithelial dysplasia. Cancer Res 62 (2002) 5295-5300
17. Braakhuis B.J., Tabor M.P., Kummer J.A., et al. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 63 (2003) 1727-1730
18. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat Med 10 (2004) 789-799
19. Mendelsohn J., and Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21 (2003) 2787-2799
20. Song J.I., and Grandis J.R. STAT signaling in head and neck cancer. Oncogene 19 (2000) 2489-2495
21. Vitale-Cross L., Amornphimoltham P., Fisher G., et al. Conditional expression of K-ras in an epithelial compartment that includes the stem cells is sufficient to promote squamous cell carcinogenesis. Cancer Res 64 (2004) 8804-8807
22. Knudson Jr. A.G. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 68 (1971) 820-823
23. Knudson A.G. Cancer genetics. Am J Med Genet 111 (2002) 96-102
24. Levine A.J., Finlay C.A., and Hinds P.W. p53 is a tumor suppressor gene. Cell 116 (2004) S67-S69
25. Vousden K.H., and Prives C. p53 and prognosis: new insights and further complexity. Cell 120 (2005) 7-10
26. Sherr C.J. Principles of tumor suppression. Cell 116 (2004) 235-246
27. Shin K.H., Kim J.M., Rho K.S., et al. Inactivation of the PTEN gene by mutation, exonic deletion, and loss of transcript in human oral squamous cell carcinomas. Int J Oncol 21 (2002) 997-1001
28. D'Andrea A.D., and Grompe M. The Fanconi anaemia/BRCA pathway. Nat Rev Cancer 3 (2003) 23-34
29. Yang Y.G., Herceg Z., Nakanishi K., et al. The Fanconi anemia group. A protein modulates homologous repair of DNA double-strand breaks in mammalian cells. Carcinogenesis (2005)
30. Marsit C.J., Liu M., Nelson H.H., et al. Inactivation of the Fanconi anemia/BRCA pathway in lung and oral cancers: implications for treatment and survival. Oncogene 23 (2004) 1000-1004
31. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
32. Rubin Grandis J., Melhem M.F., et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90 (1998) 824-832
33. Xia W., Lau Y.K., Zhang H.Z., et al. Combination of EGFR, HER-2/neu, and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res 5 (1999) 4164-4174
34. Gschwind A., Fischer O.M., and Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 4 (2004) 361-370
35. Myers J.N., Holsinger F.C., Bekele B.N., et al. Targeted molecular therapy for oral cancer with epidermal growth factor receptor blockade: a preliminary report. Arch Otolaryngol Head Neck Surg 128 (2002) 875-879
36. Yigitbasi O.G., Younes M.N., Doan D., et al. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade. Cancer Res 64 (2004) 7977-7984
37. Bonner J, Giralt J, Harari P, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab. In: Proceedings of the annual meeting of the American Society of Clinical Oncology. New Orleans, LA; June 5-8, 2004. p. 5507.
38. Yu H., and Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 4 (2004) 97-105
39. Masuda M., Suzui M., Yasumatu R., et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 62 (2002) 3351-3355
40. Grandis J.R., Drenning S.D., Chakraborty A., et al. Requirement of Stat3 but not Stat1 activation for epidermal growth factor receptor-mediated cell growth in vitro. J Clin Invest 102 (1998) 1385-1392
41. Bowman T., Garcia R., Turkson J., and Jove R. STATs in oncogenesis. Oncogene 19 (2000) 2474-2488
42. Grandis J.R., Drenning S.D., Zeng Q., et al. Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. Proc Natl Acad Sci U S A 97 (2000) 4227-4232
43. Weinberg R.A. The retinoblastoma protein and cell cycle control. Cell 81 (1995) 323-330
44. zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2 (2002) 342-350
45. Danial N.N., and Korsmeyer S.J. Cell death: critical control points. Cell 116 (2004) 205-219
46. Hipfner D.R., and Cohen S.M. Connecting proliferation and apoptosis in development and disease. Nat Rev Mol Cell Biol 5 (2004) 805-815
47. Kantak S.S., and Kramer R.H. E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells. J Biol Chem 273 (1998) 16953-16961
48. Korsmeyer S.J. Chromosomal translocations in lymphoid malignancies reveal novel proto-oncogenes. Annu Rev Immunol 10 (1992) 785-807
49. Bradley G., Irish J., MacMillan C., et al. Abnormalities of the ARF-p53 pathway in oral squamous cell carcinoma. Oncogene 20 (2001) 654-658
50. Amornphimoltham P., Sriuranpong V., Patel V., et al. Persistent activation of the Akt pathway in head and neck squamous cell carcinoma: a potential target for UCN-01. Clin Cancer Res 10 (2004) 4029-4037
51. Stoll C., Baretton G., Ahrens C., et al. Prognostic significance of apoptosis and associated factors in oral squamous cell carcinoma. Virchows Arch 436 (2000) 102-108
52. Hayflick L. Mortality and immortality at the cellular level. A review. Biochemistry (Mosc) 62 (1997) 1180-1190
53. Kim H.R., Christensen R., Park N.H., et al. Elevated expression of hTERT is associated with dysplastic cell transformation during human oral carcinogenesis in situ. Clin Cancer Res 7 (2001) 3079-3086
54. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 285 (1971) 1182-1186
55. Hicklin D.J., and Ellis L.M. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23 (2005) 1011-1027
56. Smith B.D., Smith G.L., Carter D., et al. Prognostic significance of vascular endothelial growth factor protein levels in oral and oropharyngeal squamous cell carcinoma. J Clin Oncol 18 (2000) 2046-2052
57. Winkler F., Kozin S.V., Tong R.T., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6 (2004) 553-563
58. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350 (2004) 2335-2342
59. Vasioukhin V., Bauer C., Degenstein L., et al. Hyperproliferation and defects in epithelial polarity upon conditional ablation of alpha-catenin in skin. Cell 104 (2001) 605-617
60. Margulis A., Zhang W., Alt-Holland A., et al. E-cadherin suppression accelerates squamous cell carcinoma progression in three-dimensional, human tissue constructs. Cancer Res 65 (2005) 1783-1791
61. Lim S.C., Zhang S., Ishii G., et al. Predictive markers for late cervical metastasis in stage I and II invasive squamous cell carcinoma of the oral tongue. Clin Cancer Res 10 (2004) 166-172
62. Guo W., and Giancotti F.G. Integrin signalling during tumour progression. Nat Rev Mol Cell Biol 5 (2004) 816-826
63. Christofori G., and Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem Sci 24 (1999) 73-76
64. Kupferman M.E., Fini M.E., Muller W.J., et al. Matrix metalloproteinase 9 promoter activity is induced coincident with invasion during tumor progression. Am J Pathol 157 (2000) 1777-1783
65. Katayama A., Bandoh N., Kishibe K., et al. Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. Clin Cancer Res 10 (2004) 634-640
66. Kang Y., and Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 118 (2004) 277-279
67. Yang J., Mani S.A., Donaher J.L., et al. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 117 (2004) 927-939
68. Thiery J.P. Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2 (2002) 442-454
69. O'Donnell R.K., Kupferman M., Wei S.J., et al. Gene expression signature predicts lymphatic metastasis in squamous cell carcinoma of the oral cavity. Oncogene 24 (2005) 1244-1251
70. Roepman P., Wessels L.F., Kettelarij N., et al. An expression profile for diagnosis of lymph node metastases from primary head and neck squamous cell carcinomas. Nat Genet 37 (2005) 182-186
71. van de Vijver M.J., He Y.D., van't Veer L.J., et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347 (2002) 1999-2009
72. Joyce J.A. Therapeutic targeting of the tumor microenvironment. Cancer Cell 7 (2005) 513-520